Skip to content

A randomized controlled clinical study on the impact of the Liuzijue on the psychological and social functions of patients with depression

The impact of the Liuzijue on the psychological and social functions of patients with depression

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400080631
Enrollment
Unknown
Registered
2024-02-04
Start date
2019-03-16
Completion date
Unknown
Last updated
2024-02-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depressive episode

Interventions

Liuzijue group:Liuzijue training: During the 4-week clinical intervention process, the intervention group implemented six character formula intervention on the basis of conventional drug treatment and
Control group:Routine medication treatment and routine carefor a period of 4 weeks.

Sponsors

Xiamen Xianyue Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria(ICD-10) for depressive episodes and have moderate to severe severity; (2) Hamilton Depression Scale score>17 points; (3) Age>18 years old, = 60 years old, regardless of gender; (4) Education level of primary school or above; (5) Accept standardized psychiatric medication treatment; (6) After being informed and aware of the purpose and precautions of this study, the patient or their guardian is willing to cooperate with this study and sign an informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients with severe diseases of major organs such as the heart, lungs, liver, and kidneys, such as patients with liver and kidney dysfunction, patients with severe arrhythmia or heart failure during or after myocardial infarction, and patients with respiratory failure; (2) Individuals with mental disorders caused by neurodegenerative diseases, cerebrovascular diseases, brain tumors, traumatic brain injuries, etc; (3) Abuse of psychoactive substances such as alcohol and drugs; (4) Diagnosed as a patient with mental retardation, personality disorders, or schizophrenia; (5) Individuals with serious suicidal tendencies; (6) Other situations that have been assessed by research doctors as unsuitable for participation in this study.

Design outcomes

Primary

MeasureTime frame
Changes in HAMD scale scores from baseline after 4 weeks of intervention;

Secondary

MeasureTime frame
Changes in SDS scale scores from baseline after 4 weeks of intervention;Changes in SAS scale scores from baseline after 4 weeks of intervention;Changes in the score of the SHEEHAN Disability Scale from baseline during the 4-week intervention;Changes in psychosocial function questionnaire scores from baseline after 4 weeks of intervention;

Countries

China

Contacts

Public ContactJin Gao

Xiamen Xianyue Hospital

276832794@qq.com+86 136 1604 3652

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026